La cadena de opciones muestra datos clave de las opciones de acciones de Assembly Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Assembly Biosciences..

Assembly Biosciences (NASDAQ:ASMB) Bolsa, Cadena de Opciones

Assembly Biosciences

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences Inc

WIIM

EQNR

Equinor shares are trading higher after the company announced it has received $3B in financing for its U.S. Empire Wind 1 project.

Authorities now believe the <a href="https://www.benzinga.com/25/01/42756901/fbi-probes-new-years-day-vehicle-assault-in-new-orleans-as-terrorism">New Orleans truck attack</a> suspect acted alone, contradicting earlier suspicions of the existence of accomplices, the FBI announced in a press conference on Thursday.
What Happened: The New Year's Day tragedy left 14 dead and dozens injured when Shamsud-Din Jabbar drove a pickup truck into a crowd of revelers on Bourbon Street, The New York Times <a href="https://www.nytimes.com/live/2025/01/02/us/new-orleans-attack-news">reports</a>. It was initially reported the Bourbon Street attack killed 15 people; the Times clarified Thursday that 14 people were killed plus the suspect. 
Officials said two explosive devices found at the French Quarter scene failed to detonate, adding that no definitive link has been established between the attack and the explosion outside the Trump International Hotel in Las Vegas hours later.
In Las Vegas, Matthew Livelsberger, an active duty Army soldier, allegedly drove a rented Tesla Cybertruck loaded with fireworks mortars, gasoline and camping fuel into the valet area of the hotel early on New Year's Day. The vehicle exploded, killing Livelsberger and injuring seven bystanders, ABC News <a href="https://abcnews.go.com/US/las-vegas-cybertruck-explosion-investigation-leads-police-colorado/story?id=117263085">reports</a>.
Investigators have since uncovered that both Livelsberger and Jabbar served at the same Army base, <a href="https://www.denver7.com/news/local-news/suspects-in-vegas-explosion-new-orleans-attack-served-at-same-army-base-sources-tell-denver7-investigates">according </a>to Denver7, an ABC affiliate. 
Also Read: <a href="https://www.benzinga.com/general/sports/25/01/42771050/new-orleans-beefs-up-security-ahead-of-sugar-bowl-tickets-plummet-to-25-as-fans-leave-town">New Orleans Beefs Up Security Ahead Of Sugar Bowl, Tickets Plummet To $25 As Fans Leave Town</a>
Why It Matters: The shared military base connection that was reported between Jabbar and Livelsberger has intensified scrutiny of their overlapping histories. Additionally, the use of Turo rentals in these tragedies highlights concerns about background check procedures on car-sharing platforms.
Both suspects rented electric pickup trucks: Livelsberger used a Tesla Cybertruck and Jabbar rented a Ford F-150 Lightning. The latter vehicle's owner, who rents cars for a secondary income, said he identified his truck from news footage and plans to stop using <a href="https://www.benzinga.com/media/25/01/42769136/turo-used-for-new-orleans-las-vegas-attacks-we-are-devastated-by-these-horrible-incidents">Turo after the attack.</a>
Authorities in both cities said there are no ongoing threats as investigations continue.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42768507/china-slaps-export-restrictions-on-dozens-of-us-companies-boeing-lockheed-martin-general-dynamics-raytheon-affected">China&#8217;s Export Crackdown Hits Boeing, Lockheed Martin And More</a></li>
</ul>
Photo: Shutterstock.

News

FBI Says Suspect In New Orleans Attack Acted Alone; Vegas Cybertruck Explosion Suspect Identified

Some people take saving money to a whole new level. A recent <a href="https://www.reddit.com/r/Frugal/comments/1hmfdeq/what_are_some_extreme_acts_of_frugality_that_you/">thread</a> on r/Frugal asked users to share the most &#8220;extreme acts of frugality&#8221; they've witnessed and the responses did not disappoint. From genius hacks to eyebrow-raising habits, here are some of the most memorable ones.
One user shared a story about their grandfather, who would walk to the local grocery store daily to grab a complimentary coffee sample. He'd drink the small Dixie cup-sized serving and then walk home without buying a thing. According to the person, he &#8220;lived a great ultra-<a href="https://www.benzinga.com/news/24/05/38628868/warren-buffetts-frugal-lifestyle-hacks-saved-millions-here-are-5-tips-to-follow-suit-in-your-everyda">frugal life</a> as he saw it. We didn't know much about his finances, but he needed very little in life. He left behind over a quarter of a million dollars in his bank, a house he owned and a gently used Toyota in the early 2000s.&#8221;
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
Another person&#8217;s grandmother's clever recycling also made an impression. As socks wore out, she'd darn them and pass them down to younger family members. When the socks became too short, she'd cut off the tops and sew them over worn coat sleeves. As someone noted, &#8220;I imagine this only works with real textiles. The polyester clothes that they sell now would never.&#8221;
A person&#8217;s father had a nightly ritual that involved turning off the Wi-Fi router to <a href="https://www.benzinga.com/personal-finance/24/08/40431920/customers-who-save-on-electric-bills-might-have-to-pay-extra-utility-companies-could-charge-them">save on electricity</a>. While the actual savings were probably pennies, the habit sparked debates about how far people would go to pinch a penny.
Another crafty idea involved fabric strips dipped in a cornstarch-water mixture to seal drafts around windows and doors. Not only is it effective, but it's also an old-school trick that's stood the test of time– &#8220;I did this as a privacy screen on my biggest windows, but I appreciate the small amounts of heat savings they offer, though it was not my primary goal.&#8221;
See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Some folks took eco-frugality to another level by flushing their toilets with grey water from washing dishes or showers. One person even calculated that while this practice saved them next to nothing, it gave them a sense of satisfaction for using less.
In one of the more polarizing examples, someone's ex insisted on skipping seasonings altogether to <a href="https://www.benzinga.com/money/how-to-save-money-fast">save money</a>, claiming the calories-per-dollar ratio wasn't worth it. This led to three months of bland, unseasoned rice and beans until the poster finally stole a salt shaker. "Worth it," they said. For one commenter, this was unhinged because, as they put it, a pound of salt is &#8220;like $1 and lasts forever.&#8221; Is it worth eating bland food every day just to save on that? They finally asked.
One commenter mentioned their sister, who wore her wedding dress from a previous marriage to her second wedding. While it raised eyebrows, others applauded the practicality. After all, it's just a dress.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
The thread also included stories about people cutting expiration dates off coupons, reusing disposable cups to claim "free" refills and dumpster diving for receipts to get freebies at fast-food restaurants.
Many users pointed out that extreme frugality often stems from past experiences with poverty or financial insecurity. One commenter reflected on how their grandparents, who lived through the Great Depression, saved everything from aluminum lids to juice concentrate tubes. It was less about saving money and more about the fear of waste and scarcity.
From hilarious to heartwarming, these stories show how far people will go to save a dollar. Whether it's a quirky habit or a creative solution, there's no denying that extreme frugality takes ingenuity – and maybe just a little madness!
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
</ul>

Personal Finance

'This Is Unhinged' – A Reddit User Asks Others For 'Extreme Acts Of Frugality' They Witnessed And The Replies Are Shockingly Entertaining

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) is surging on Thursday, driven by positive community developments and notable whale movements.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.43</td>
<td>$139.4 billion</td>
<td>+8.9%</td>
<td>+11.5%</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$97,254.11</td>
<td>$1.92 trillion</td>
<td>+3.8%&nbsp;</td>
<td>+0.8%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,471.67</td>
<td>$418.4 billion</td>
<td>+4.5%&nbsp;</td>
<td>+3.4%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Credibull Crypto commented "so far, so good" on the price surge, targeting the highs set by XRP in November.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Blue zone tapped as expected and a beautiful reaction off of it after. So far so good.<a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> <a href="https://t.co/R8YQvesfrA">https://t.co/R8YQvesfrA</a> <a href="https://t.co/YGoEWpe9sR">pic.twitter.com/YGoEWpe9sR</a>
&mdash; CrediBULL Crypto (@CredibleCrypto) <a href="https://twitter.com/CredibleCrypto/status/1874552098861523319?ref_src=twsrc%5Etfw">January 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Captain Faibik projected a bullish rally of another 50%, <a href="https://x.com/CryptoFaibik/status/1874686070312345730">targeting</a> a price of $3.66. 
Statistics: Whale Alert data <a href="https://x.com/whale_alert/status/1874453215451738346">shows</a> 300 million XRP, worth $649.8 million, transferred from an unknown wallet to Ripple. 
Another major <a href="https://x.com/whale_alert/status/1874349148662534270">transfer</a> of 500 million XRP, worth $1.07 billion, was unlocked from escrow at unknown wallet.  
The enterprise behind the Ripple payment protocol and exchange network, initiated this transfer.
Another transaction <a href="https://x.com/whale_alert/status/1874330664176062712">shows</a> 30 million XRP, worth $64 million, was transferred from an unknown wallet to Bitthumb.  
Crypto trader Ali Martinez noted whales having purchased 360 million XRP in the past 48 hours.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Whales bought 360 million <a href="https://twitter.com/search?q=%24XRP&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$XRP</a> in the past 48 hours! <a href="https://t.co/w9OnuOK2x1">pic.twitter.com/w9OnuOK2x1</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1874837397617381798?ref_src=twsrc%5Etfw">January 2, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Whale activity has sparked curiosity among traders and fueled optimism for XRP, with the altcoin&#8217;s open interest surging by 27.2% in just one day, reaching $2.5 billion. 
According to Coinglass, derivatives trading volume skyrocketed by 195.4%, climbing to $12.19 billion.
Community News: Following the <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42423570/ripple-secures-nydfs-approval-for-rlusd-stablecoin-xrp-price-up-9">approval of Ripple&#8217;s RLUSD stablecoin</a>, community news have been buzzing with bullish rumors.
The Crypto Times <a href="https://www.cryptotimes.io/2024/12/30/80-of-japanese-banks-set-to-adopt-ripples-xrp-by-2025/">speculates</a> that nearly 80% of Japanese banks plan to adopt XRP by 2025, though the outlet did not cite a source for this figure.
A Binance community article mused that Ripple picking up the $300 trillion in global cross-border payments could cause XRP&#8217;s price to <a href="https://www.binance.com/en-IN/square/post/18238109732026">reach</a> $5,769. 
While XRP's integration into Ripple products solidifies its reputation in the cross-border payments market, this target is mere speculation and should more be taken as an indicator of bullish sentiment than as tangible development.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42736132/top-trader-paints-5x-jump-for-xrp-as-crypto-shows-one-of-the-most-promising-setups-heading-into-2025">XRP Poised For 450% Upside, Says Analyst, As Coin Shows &#8216;One Of The Most Promising Setups&#8217; Heading Into 2025</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Price Surges 9%: What Is Going On With Ripple?

Trading Ideas

XPON

Expion360 Shares Resumed Trade

Dr. Zachary Levy&#8216;s viral post on X has amplified frustrations with the <a href="https://www.benzinga.com/general/health-care/24/12/42744629/unitedhealth-group-ceo-reportedly-says-company-will-hit-financial-records-execs-murder-public-outcry-are-backdrop-for-q4-earnings" target="_blank" rel="noreferrer noopener">U.S. health insurance system</a>.
Levy said UnitedHealthcare Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) denied coverage for one of his ICU patients. He cited insufficient evidence of medical necessity despite the patient being in a coma and suffering from multiple life-threatening conditions.
Levy&#8217;s Dec. 30 <a href="https://x.com/ZLevyMD/status/1873925592242115036?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1873925592242115036%7Ctwgr%5E20ae2a4723e8e2644de0a2f75b39f78be9b9d9bd%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fwww.newsweek.com%2Funited-healtchare-claim-deny-brian-thompson-luigi-mangione-insurance-2008307&amp;mx=2" target="_blank" rel="noreferrer noopener">post</a> garnered over 13 million views and reignited debates about insurer practices with a blunt quote: &#8220;Tear it all down.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">United Healthcare <a href="https://twitter.com/UHC?ref_src=twsrc%5Etfw">@UHC</a> just denied a claim on one of my patients in the ICU with: &#8212; a brain hemorrhage &#8212; in a coma &#8212; on a ventilator &#8212; in heart failure &#8230;because I haven&#39;t proven to them that caring for her in the hospital was &quot;medically necessary&quot;. Tear it all down.
&mdash; Zachary D Levy MD &#x1f1f2;&#x1f1e6; &#x1f1e8;&#x1f1ee; (@ZLevyMD) <a href="https://twitter.com/ZLevyMD/status/1873925592242115036?ref_src=twsrc%5Etfw">December 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Benzinga emailed United Healthcare for comment on Levy&#8217;s allegations. 
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/24/12/42621731/nebraska-attorney-general-sues-unitedhealth-over-massive-data-breach-that-disrupted-healthcare" rel="noreferrer noopener">Nebraska Attorney General Sues UnitedHealth Over Massive Data Breach That Disrupted Healthcare</a>
Levy shared an email he wrote to UnitedHealthcare describing the patient&#8217;s treatment as critical for survival.
Newsweek&#8217;s <a href="https://www.newsweek.com/united-healtchare-claim-deny-brian-thompson-luigi-mangione-insurance-2008307" target="_blank" rel="noreferrer noopener">report</a> highlights UnitedHealthcare has faced lawsuits over its practices, including allegations that an AI tool used by the company resulted in a high error rate and denied necessary care to many patients.
The insurance giant has garnered immense attention following the murder of its insurance unit CEO, Brian Thompson, in New York.
Luigi Mangione, the alleged perpetrator, pleaded not guilty to murder and weapons charges. Police found shell casings at the scene with the words &#8220;deny,&#8221; &#8220;defend,&#8221; and &#8220;depose,&#8221; commonly associated with insurance industry strategies for <a href="https://www.benzinga.com/24/12/42710544/can-you-bet-on-luigi-mangiones-fate-betting-platforms-regulators-wrestle-with-limits" target="_blank" rel="noreferrer noopener">handling claims and disputes</a>.
Authorities believe the crime may reflect a personal vendetta against UnitedHealthcare or the broader industry.
The homicide has brought fresh attention to systemic issues within the health insurance sector, with many calling for reforms. Executives have pledged to address these concerns, but critics remain skeptical about meaningful change.
Adding to the debate, media <a target="_blank" href="https://www.unitedhealthgroup.com/newsroom/2024/2024-12-uhg-response-wsj-recent-reporting-medicare-advantage.html" rel="noreferrer noopener">reports</a> have scrutinized Medicare Advantage (MA) plans administered by companies like UnitedHealthcare.
However, proponents argue MA programs outperform traditional Medicare by emphasizing early diagnosis, coordinated care, and value-based clinical models, leading to better health outcomes and lower costs for seniors.
UnitedHealthcare claims its MA plans are delivering on their intended purpose despite negative portrayals.
As public scrutiny intensifies, calls for accountability and transparency within the insurance industry grow louder, fueled by high-profile incidents and ongoing patient struggles.
Meanwhile, UnitedHealthcare has <a target="_blank" href="https://www.unitedhealthgroup.com/newsroom/2024/2024-12-13-uhg-statement-claims-misinformation.html" rel="noreferrer noopener">defended</a> its claim practices, stating it approves approximately 90% of claims upon submission, with less than 0.5% requiring further medical review. The company labeled recent criticisms as &#8220;highly inaccurate and grossly misleading.&#8221;
Price Action: UnitedHealthcare stock is down 0.02% at $505.76 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/42767647/chinese-stocks-drop-as-manufacturing-growth-slows-and-geopolitical-tensions-hit" target="_blank" rel="noreferrer noopener">Chinese Stocks Drop As Manufacturing Growth Slows And Geopolitical Tensions Hit</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

General

Viral 'Tear It All Down' Post Sparks Debate Over UnitedHealthcare Practices, Alleges Denial Of ICU Care For Comatose Patient

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust
The SPY is currently trading near our pivotal level of 592.00. For bullish scenarios, buyers will aim for an initial move to 593.73. Sustained price action above 593.73 could lead to a push toward 596.57. If this level is maintained as support during regular trading hours, further upside potential exists, targeting 598.04. Our ambitious bull target for SPY today is set at 599.24.
On the downside, failure to maintain 592.00 as support could see sellers testing 589.71. If downward momentum intensifies, 587.31 becomes a critical level to watch. A breakdown below this support opens the door to 585.75. In an aggressive sell-off, we anticipate SPY could reach our low bear target of 584.68.
Invesco QQQ Trust Series 1
The QQQ is hovering around the critical 517.97 level. Bulls need to assert dominance here, pushing the price higher to reclaim 519.87 as a solid support. If buyers remain consistent, a move toward 521.15 is expected. Continued strength in the auction could result in a test of 522.57, with our high bull target for the day at 523.91.
Conversely, inability to hold 517.97 during the session could shift control to the bears, leading to a retest of 516.58. Should selling pressure intensify, 515.00 and eventually 513.64 could come into play. Persistent bearish activity may drive the QQQ down to the low bear target of 511.53.
Apple Inc. 
Apple is currently trading near 250.39, a key level for today's session. Bulls need to maintain this level as support to pave the way for a rally to 252.13. If momentum builds, we could see further upside action toward 253.90. A sustained rally may ultimately lead to Apple reaching our high bull target of 255.16.
Failure to hold 250.39 as support could signal bearish intentions, driving the price lower to 249.04. Continued selling pressure might result in a move down to 248.12. If this level fails, 246.72 becomes the next target, with a deeper bearish session pushing Apple to the low bear target of 245.58.
Microsoft Corp. 
Microsoft is trading near the 427.36 level. Bulls need to maintain this as a support area to encourage a rally to 428.48. Holding above this level could fuel further upward movement toward 429.25. Should buying momentum persist, we expect Microsoft to test the high bull target of 430.25.
On the flip side, a failure at 427.36 might invite selling, leading to a drop to 426.00. Continued bearish momentum could press the price down to 425.16. If this weakness continues, we foresee a test at 423.81, with the low bear target for the day at 422.84.
NVIDIA Corporation NVIDIA is trading near its pivotal level of 136.98. Bulls must reclaim 137.94 as a firm support level to set the stage for a rally to 138.55. If the buying trend holds, further advances to 139.42 are possible, with our high bull target on the day at 140.28.
Failure to sustain 136.98 could bring bears into play, testing 135.64. If selling continues, the price could fall to 134.56. Persistent downside action might see NVIDIA probing 133.31, with the low bear target for the day at 132.19.
Alphabet Inc Class A 
Alphabet is trading near the key level of 191.45. Bulls should aim to hold this level as support and push toward 192.19. A strong bullish presence could propel the price higher to 193.14, the high bull target for today.
If 191.45 fails to act as support, bears may test the downside at 190.41. A breakdown at this level could lead to 189.57. Heavy selling might result in Alphabet testing its low bear target at 188.73.
Meta Platforms Inc 
Meta is trading around 591.29, a critical level for today&#8217;s auction. Bulls need to hold this level and drive the price higher to 598.17. Sustained bullish momentum could lead to further advances toward 604.50, with the high bull target set at 609.30.
Should 591.29 fail to hold as support, bears may seize control, pushing the price down to 585.73. Continued sell-side activity could test 580.17. If this level breaks, Meta could reach the low bear target of 573.25.
Tesla Inc. 
Tesla is trading near 407.97, an important level to watch. Bulls will aim for an initial move to 413.10. If buying interest continues, the price could rally further to 416.62. A strong session might see Tesla testing 420.70, with the high bull target set at 426.23.
If 407.97 cannot hold, bears may target 403.43. Continued selling could drive Tesla lower to 399.03. If bearish pressure persists, Tesla might reach the low bear target of 390.23.
Final Word: As the first trading session of 2025 begins, today is marked by several key events. At 8:30 AM ET, the market will digest the Initial and Continuing Jobless Claims, providing early insights into the labor market. Shortly after, at 9:45 AM ET, the release of the Final S&amp;P Global Manufacturing PMI for December will offer a snapshot of economic health.
Midday, at 11:30 AM ET, the Treasury&#8217;s 4 and 8 week Bill Auction could impact short-term yields. With many institutional desks still on holiday, trading may lack liquidity, leading to potential spikes in volatility. Traders are advised to exercise caution, manage risk effectively, and stay prepared for rapid market movements. Have a productive session, trade wisely, and cheers to a prosperous 2025!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Market Clubhouse Morning Memo - January 2nd, 2024 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META and TSLA)

On Thursday, Xcel Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) announced that it will extend the operation of its Monticello Nuclear Generating Plant, following a recent license renewal by the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42767152/xcel-energys-monticello-nuclear-plant-receives-federal-approval-to-extend-operations" rel="noreferrer noopener">U.S. Nuclear Regulatory Commission.</a>
The federal approval allows the plant to continue operating for an additional 20 years, until 2050, subject to approval by state regulators. This extension is pivotal to Xcel Energy&#8217;s goal of achieving 100% carbon-free electricity by reinforcing the role of nuclear energy in its clean energy transition.
The Monticello plant has been a vital source of clean, safe, and reliable energy for more than 500,000 homes in the Upper Midwest.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/global/24/12/42743937/natural-gas-prices-spike-as-bone-chilling-arctic-blast-approaches" rel="noreferrer noopener">Natural Gas Prices Spike As &#8216;Bone-Chilling&#8217; Arctic Blast Approaches</a>
Xcel Energy Chairman, President, and CEO Bob Frenzel emphasized the importance of the plant in accelerating the company&#8217;s clean energy journey.
&#8220;As the only 24/7 carbon-free energy source we have, nuclear energy will be key to accelerating our journey to a clean energy future while ensuring we also meet the unprecedented growth in our customers&#8217; demand for electricity,&#8221; Frenzel added.
The NRC&#8217;s decision follows a thorough multi-year review process, including extensive inspections, audits, and technical assessments to ensure the plant meets rigorous safety and environmental standards.
The Minnesota Public Utilities Commission has already approved extending Monticello&#8217;s operations through 2040, and Xcel Energy will seek further approval for the remaining 10 years.
In addition to its environmental role, the Monticello plant is a major economic contributor to the region, providing significant employment and tax revenue to the local community.
Price Action: XEL shares are trading lower by 0.64% to $67.09 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/12/42734220/bill-ackman-sends-fannie-mae-freddie-mac-stocks-soaring-trump-likes-big-deals" target="_blank" rel="noreferrer noopener">Bill Ackman Sends Fannie Mae, Freddie Mac Stocks Soaring: &#8216;Trump Likes Big Deals&#8217;</a> </li>
</ul>
Photo via Shutterstock.

Equities

Markets

Xcel Energy Secures 20-Year License Extension For Monticello Nuclear Plant, Boosting Clean Energy Goals

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $136.5, along with a high estimate of $160.00 and a low estimate of $114.00. This current average has decreased by 7.28% from the previous average price target of $147.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1735840847_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Sun Communities among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$135.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$131.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$134.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$114.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>John Kim</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$135.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$126.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$150.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$160.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sun Communities. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sun Communities compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Sun Communities's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Sun Communities's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sun Communities analyst ratings.</a>
<h2>Get to Know Sun Communities Better</h2>
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
<h3>Sun Communities's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Sun Communities's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -3.48%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 30.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sun Communities's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.0% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Sun Communities's ROA stands out, surpassing industry averages. With an impressive ROA of 1.68%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.98.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Sun Communities: Insights From 10 Financial Analysts

Financial giants have made a conspicuous bullish move on Datadog. Our analysis of options history for Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) revealed 13 unusual trades.
Delving into the details, we found 69% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $110,385, and 11 were calls, valued at $946,161.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $120.0 to $180.0 for Datadog over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Datadog's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Datadog's whale trades within a strike price range from $120.0 to $180.0 in the last 30 days. 
<h3>Datadog Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735840844_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.75</td>
<td>$5.55</td>
<td>$5.75</td>
<td>$180.00</td>
<td>$345.0K</td>
<td>1.0K</td>
<td align="right">600</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.65</td>
<td>$8.45</td>
<td>$8.56</td>
<td>$150.00</td>
<td>$83.4K</td>
<td>1.4K</td>
<td align="right">851</td>
</tr>
<tr>
<td>DDOG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/10/25</td>
<td>$10.15</td>
<td>$8.95</td>
<td>$8.95</td>
<td>$152.50</td>
<td>$83.2K</td>
<td>489</td>
<td align="right">123</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.75</td>
<td>$8.6</td>
<td>$8.66</td>
<td>$150.00</td>
<td>$74.3K</td>
<td>1.4K</td>
<td align="right">423</td>
</tr>
<tr>
<td>DDOG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$26.25</td>
<td>$25.3</td>
<td>$25.3</td>
<td>$120.00</td>
<td>$68.3K</td>
<td>2.4K</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Datadog</h3>
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses.
In light of the recent options history for Datadog, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Datadog's Current Market Status</h3>
<ul>
<li>With a trading volume of 1,168,225, the price of DDOG is down by -0.62%, reaching $142.0.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 40 days from now.</li>
</ul>
<h3>Expert Opinions on Datadog</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $184.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Macquarie downgraded its action to Outperform with a price target of $200. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Datadog, which currently sits at a price target of $187. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Datadog, targeting a price of $170. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Datadog with a target price of $165. 
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Buy rating for Datadog, targeting a price of $200. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Datadog options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

DDOG

Decoding Datadog's Options Activity: What's the Big Picture?

In the latest quarter, 4 analysts provided ratings for Douglas Emmett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEI#NYSE">DEI</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Douglas Emmett and provided 12-month price targets. The average target is $19.75, accompanied by a high estimate of $21.00 and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 16.18% from the previous average price target of $17.00.
<img src="https://www.benzinga.com/files/images/story/2025/1735840841_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Douglas Emmett among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$21.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$19.00</td>
<td>$16.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Douglas Emmett. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Douglas Emmett compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Douglas Emmett's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Douglas Emmett's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DEI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Douglas Emmett analyst ratings.</a>
<h2>About Douglas Emmett</h2>
Douglas Emmett Inc is a real estate investment trust that acquires, develops, and manages office and multifamily properties in Los Angeles, California and Honolulu, Hawaii in the U.S. The company focuses on owning assets in communities with large supply constraints, such as the affluent neighborhoods of Los Angeles. The vast majority of Douglas Emmett's real estate portfolio is comprised of office buildings in Los Angeles. Most of these assets are located in the areas of Sherman Oaks, Woodland Hills, and Beverly Hills in terms of total square feet. Douglas Emmett derives nearly all of its income in the form of rental revenue from tenants. The vast majority of this also comes from its Los Angeles office buildings. The company's major tenants are legal, financial, and entertainment firms.
<h3>Understanding the Numbers: Douglas Emmett's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Douglas Emmett's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -1.82%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Douglas Emmett's ROE stands out, surpassing industry averages. With an impressive ROE of 0.2%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Douglas Emmett's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.05%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 2.64, Douglas Emmett faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Douglas Emmett Through The Eyes Of 4 Analysts

High-rolling investors have positioned themselves bearish on Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CRDO often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Credo Technology Group. This is not a typical pattern.
The sentiment among these major traders is split, with 11% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $27,360, and 8 calls, totaling $262,033.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $50.0 to $110.0 for Credo Technology Group over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Credo Technology Group stands at 567.67, with a total volume reaching 1,982.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Credo Technology Group, situated within the strike price corridor from $50.0 to $110.0, throughout the last 30 days.
<h3>Credo Technology Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735840839_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.9</td>
<td>$5.7</td>
<td>$5.76</td>
<td>$65.00</td>
<td>$40.3K</td>
<td>732</td>
<td align="right">517</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.9</td>
<td>$5.6</td>
<td>$5.7</td>
<td>$65.00</td>
<td>$39.9K</td>
<td>732</td>
<td align="right">587</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$6.8</td>
<td>$4.9</td>
<td>$5.7</td>
<td>$65.00</td>
<td>$39.8K</td>
<td>732</td>
<td align="right">70</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.9</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$70.00</td>
<td>$37.0K</td>
<td>1.4K</td>
<td align="right">241</td>
</tr>
<tr>
<td>CRDO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$19.8</td>
<td>$18.8</td>
<td>$19.0</td>
<td>$65.00</td>
<td>$28.5K</td>
<td>32</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Credo Technology Group</h3>
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.
After a thorough review of the options trading surrounding Credo Technology Group, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Credo Technology Group</h3>
<ul>
<li>With a trading volume of 1,691,214, the price of CRDO is up by 1.71%, reaching $68.36.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>Expert Opinions on Credo Technology Group</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $72.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Susquehanna lowers its rating to Neutral with a new price target of $80. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Credo Technology Group with a target price of $65. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Credo Technology Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

CRDO

What the Options Market Tells Us About Credo Technology Group

Deep-pocketed investors have adopted a bearish approach towards Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JNJ usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Johnson &amp; Johnson. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 55% bearish. Among these notable options, 2 are puts, totaling $63,388, and 7 are calls, amounting to $254,697.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $130.0 to $150.0 for Johnson &amp; Johnson over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Johnson &amp; Johnson's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Johnson &amp; Johnson's whale trades within a strike price range from $130.0 to $150.0 in the last 30 days. 
<h3>Johnson &amp; Johnson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1735840834_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$26.05</td>
<td>$25.0</td>
<td>$25.4</td>
<td>$130.00</td>
<td>$50.8K</td>
<td>31</td>
<td align="right">54</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$25.65</td>
<td>$25.25</td>
<td>$25.3</td>
<td>$130.00</td>
<td>$50.6K</td>
<td>31</td>
<td align="right">94</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.4</td>
<td>$13.0</td>
<td>$13.26</td>
<td>$140.00</td>
<td>$39.7K</td>
<td>53</td>
<td align="right">30</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.15</td>
<td>$8.0</td>
<td>$8.15</td>
<td>$140.00</td>
<td>$31.7K</td>
<td>1.7K</td>
<td align="right">39</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$15.8</td>
<td>$15.15</td>
<td>$15.8</td>
<td>$150.00</td>
<td>$31.6K</td>
<td>116</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
After a thorough review of the options trading surrounding Johnson &amp; Johnson, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Johnson &amp; Johnson</h3>
<ul>
<li>With a volume of 1,969,865, the price of JNJ is down -0.2% at $144.33. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 20 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $170.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $166. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Johnson &amp; Johnson, targeting a price of $175. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Johnson &amp; Johnson with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In JNJ Options

Throughout the last three months, 17 analysts have evaluated Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $56.71, along with a high estimate of $65.00 and a low estimate of $46.00. This current average represents a 7.22% decrease from the previous average price target of $61.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1735840833_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Schlumberger's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$59.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Phillip Jungwirth</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Schlumberger. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Schlumberger compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Schlumberger's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Schlumberger's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Schlumberger analyst ratings.</a>
<h2>Discovering Schlumberger: A Closer Look</h2>
SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts well over $1 billion in digital-related revenue.
<h3>Schlumberger: Delving into Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Schlumberger's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.22%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Schlumberger's net margin excels beyond industry benchmarks, reaching 12.95%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Schlumberger's ROE excels beyond industry benchmarks, reaching 5.57%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.39%, the company showcases effective utilization of assets.
Debt Management: Schlumberger's debt-to-equity ratio is below the industry average. With a ratio of 0.6, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Schlumberger In The Eyes Of 17 Experts

In the last three months, 18 analysts have published ratings on Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $163.14, along with a high estimate of $198.00 and a low estimate of $127.00. This current average reflects an increase of 2.93% from the previous average price target of $158.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1735840826_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Hyatt Hotels among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$176.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$161.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Joseph Greff</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$167.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$157.50</td>
<td>$145.50</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$153.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$198.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Michael Bellisario</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$158.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$144.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>Carlo Santarelli</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$127.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$164.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Meredith Jensen</td>
<td>HSBC</td>
<td>Announces</td>
<td>Hold</td>
<td>$156.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$178.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Shaun Kelley</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Duane Pfennigwerth</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$155.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$169.00</td>
<td>$164.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Hyatt Hotels. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Hyatt Hotels compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Hyatt Hotels's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Hyatt Hotels's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/H/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Hyatt Hotels analyst ratings.</a>
<h2>All You Need to Know About Hyatt Hotels</h2>
Hyatt is an operator of owned (4% of total rooms) and managed and franchised (96%) properties across around 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 54% Americas, 22% rest of world, and 23% Asia-Pacific.
<h3>Key Indicators: Hyatt Hotels's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Hyatt Hotels showcased positive performance, achieving a revenue growth rate of 0.43% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Hyatt Hotels's net margin excels beyond industry benchmarks, reaching 28.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 12.48%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Hyatt Hotels's ROA excels beyond industry benchmarks, reaching 3.83%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.93, Hyatt Hotels adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Hyatt Hotels Through 18 Analysts

Analysts' ratings for Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Biogen, presenting an average target of $224.76, a high estimate of $300.00, and a low estimate of $138.00. A 15.18% drop is evident in the current average compared to the previous average price target of $265.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1735840816_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Biogen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$138.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$164.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$178.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$180.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$207.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$204.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Biogen's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Biogen's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>All You Need to Know About Biogen</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Biogen: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Biogen's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -2.55% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Biogen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.76% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.41%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.41, Biogen adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIIB

17 Analysts Assess Biogen: What You Need To Know

VICI Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $34.0, a high estimate of $35.00, and a low estimate of $33.00. Experiencing a 0.73% decline, the current average is now lower than the previous average price target of $34.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1735840808_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of VICI Props among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to VICI Props. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of VICI Props compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of VICI Props's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of VICI Props's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VICI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on VICI Props analyst ratings.</a>
<h2>Unveiling the Story Behind VICI Props</h2>
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, and entertainment destinations, subject to long-term triple net leases. The company's operating segments are real property business and golf course business. The Real property business segment consists of leased real property whereas the Golf course business segment consists of several golf courses. Its golf courses include the Cascata Golf Course, the Rio Secco Golf Course, the Grand Bear Golf Course, and the Chariot Run Golf Course.
<h3>VICI Props: Financial Performance Dissected</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: VICI Props displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 6.67%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Net Margin: VICI Props's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 75.97%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): VICI Props's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.83% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): VICI Props's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.64%, the company showcases efficient use of assets and strong financial health.
Debt Management: VICI Props's debt-to-equity ratio is below the industry average. With a ratio of 0.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VICI

A Glimpse Into The Expert Outlook On VICI Props Through 4 Analysts

Expion360 Shares Halted On Circuit Breaker To The Downside, Stock Now Down 7.53%

Offerings

Expion360 Announces $2.6M Registered Direct And Private Placement

Nova Minerals Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVA#NASDAQ">NVA</a>) shares are trading higher Thursday after the company com pleted the sale of its 6.6 million shares in Snow Lake Resources Ltd., generating <a href="https://www.benzinga.com/25/01/42762974/nova-minerals-completes-673-million-sale-of-snow-lake-shares-strengthening-balance-sheet">$6.73 million in gross proceeds.</a>
The company allocated $4 million of the proceeds to partially repay its Nebari loan, reducing the outstanding balance to $1.42 million. The remaining funds will be used to support exploration and development at Nova's Estelle Gold and Critical Minerals Project in Alaska.
The Estelle project focuses on gold and antimony, with the latter being classified as a critical mineral due to its industrial and defense applications. The additional funding will allow the company to progress its exploration and development activities, particularly at the RPM site and other antimony prospects.
Nova also reported raising $0.79 million through the exercise of 109,237 warrants over recent months, further bolstering its financial position.
NVA Price Action: Nova Minerals shares were up 9.40% at $15.13 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072924&amp;t=be2bearmibe3na1">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02115357/Screenshot-2025-01-02-at-11.53.31-1024x522.png" alt="" class="wp-image-715622" style="width:487px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02115357/Screenshot-2025-01-02-at-11.53.31-1024x522.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02115357/Screenshot-2025-01-02-at-11.53.31-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02115357/Screenshot-2025-01-02-at-11.53.31-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02115357/Screenshot-2025-01-02-at-11.53.31-1536x783.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02115357/Screenshot-2025-01-02-at-11.53.31.png 1558w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42769289/why-blackberry-stock-is-gaining-today">BlackBerry Rebrands IoT Division As QNX &#8211; What&#8217;s Driving The Change?</a></li>
</ul>
Photo by solarseven on Shutterstock.

Movers

Nova Minerals Shares Are Up Today: What's Going On?

Capitulation in biotech is near, as well as a rally – Piper Sandler

Assembly Biosciences GAAP EPS of -$1.51, revenue of $6.85M

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Assembly Biosciences (ASMB – Research Report) today. The company's shares closed last F...

H.C. Wainwright Keeps Their Hold Rating on Assembly Biosciences (ASMB)

Assembly Biosciences Inc ( ($ASMB) ) has released its Q3 earnings. Here is a breakdown of the information Assembly Biosciences Inc presented to its...

Assembly Biosciences Reports Q3 2024 Financials and Strategic Advances

Assembly Biosciences (ASMB) announced an equity investment of $20.1M by Gilead Sciences (GILD) to purchase additional Assembly Bio common stock and...

Assembly Biosciences announces $30.1M investment, funding from Gilead

Gilead raises Assembly Bio stake to ~30%

Assembly Biosciences (ASMB) announced interim safety, pharmacokinetic, PK, and efficacy results from participants with chronic hepatitis B virus, H...

Assembly Biosciences announces interim PK, efficacy from Phase 1b study

Assembly Bio spikes after early-stage data for Gilead-partnered Hep B therapy

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Assembly Biosciences (ASMB – Research Report). The company's s...

H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)

H.C. Wainwright notes that Assembly Biosciences (ASMB) announced an interim safety, pharmacokinetics and efficacy dataset from an ongoing Phase 1b ...

H.C. Wainwright stays Neutral on Assembly Biosciences after ABI-4334 data

ASMB

CDNA

DTIL

EXEL

GILD

IBBQ

IDNA

NTRA

PRAX

PTGX

SPRY

TRDA

Press Releases

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Biotech

Assembly Biosciences Announces $12.6 Million in Equity Financings

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Earnings

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

Financing

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Comments

Assembly Biosciences

Assembly Biosciences (ASMB) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL